Enovis (NYSE:ENOV) Director Angela Lalor Purchases 887 Shares of Company Stock

Enovis Corporation (NYSE:ENOV) Director Angela Lalor bought 887 shares of the stock in a transaction on Tuesday, November 10th. The shares were purchased at an average price of $28.28 per share, with a total value of $25,084.36. Following the acquisition, the director owned 32,373 shares in the company, valued at approximately $915,508.44. This represents a 2.82% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Enovis Stock Down 3.2%

Shares of ENOV traded down $0.92 during midday trading on Thursday, hitting $27.63. The stock had a trading volume of 1,153,270 shares, compared to its average volume of 1,886,113. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of -3.00 and a beta of 1.31. The company has a 50 day simple moving average of $20.36 and a two-hundred day simple moving average of $23.19. Enovis Corporation has a twelve month low of $16.70 and a twelve month high of $31.81. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.15 and a quick ratio of 1.08.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.88 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.11. The company had revenue of $558.73 million during the quarter, compared to analysts’ expectations of $557.12 million. Enovis had a positive return on equity of 13.23% and a negative net margin of 22.86%. Enovis’s revenue for the quarter was up 1.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.75 earnings per share. On average, analysts anticipate that Enovis Corporation will post 3.15 EPS for the current year.

Institutional Investors Weigh In On Enovis

Several large investors have recently made changes to their positions in the stock. IFP Advisors Inc grew its stake in shares of Enovis by 5,590.5% in the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock valued at $25,000 after buying an additional 1,174 shares in the last quarter. Allworth Financial LP acquired a new position in Enovis during the second quarter worth $36,000. Integrated Wealth Concepts LLC acquired a new position in Enovis during the second quarter worth $39,000. Public Employees Retirement System of Ohio bought a new stake in Enovis during the second quarter worth $48,000. Finally, SBI Securities Co. Ltd. bought a new stake in Enovis during the third quarter worth $55,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on ENOV. Citizens Jmp cut their target price on Enovis from $55.00 to $47.00 and set a “market outperform” rating on the stock in a research note on Wednesday, September 2nd. BTIG Research raised their price target on shares of Enovis from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. BMO Capital Markets set a $27.00 price objective on shares of Enovis in a report on Tuesday, September 1st. Weiss Ratings raised shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, November 2nd. Finally, Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $38.62.

Enovis Company Profile

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.